Skip to main content Skip to search Skip to main navigation

EC: New Entries in the MDCG Borderline Manual

The Medical Device Coordination Group (MDCG) has updated its manual on the classification of products that are on the borderlines between medtech and other regulatory categories (Version 4).

The following newly added cases illustrate current regulatory decisions on qualification and classification:

  • Red blood cell additive solutions containing adenine
    Medical Device, Class III
    Adenine exerts metabolic/pharmacological effects on RBCs; therefore, the solution is classified as part of a Class III device.
  • Dual-action cream with menthol and capsaicin
    Not a medical device
    Principal mode of action is pharmacological (via receptor activity); classified as a medicinal product.
  • Lactose vaginal tablets
    Not a medical device
    Mode of action is metabolic, based on lactic acid bacteria metabolizing lactose into lactic acid.
  • Microabrasion dental stain removers (tooth whitening)
    Not a medical device
    Purely cosmetic purpose (aesthetic improvement), no proven medical benefit.
  • Medical examination table covers
    Medical device
    Intended to prevent disease transmission (infection prevention), thus meeting the definition of a medical device.
  • Mobile sterile air system
    Not a medical device
    Controls the environment (air purification/laminar flow), without direct action in or on the human body.

The updates highlight the strict distinction between medical purpose and cosmetic, pharmacological, or purely environmental functions. Manufacturers must provide robust scientific evidence of the principal mode of action to ensure correct regulatory qualification.


Source:

EC: Manual on borderline and classification for medical devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next